Friday, June 12, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 118 of 1,261
  1. US 11980636

    Treatment of hematological disorders

    Jazz Pharmaceuticals Ireland Limited Β· Granted May 14, 2024 Β· Expires May 9, 2044

    granted
  2. US 11980640

    Bicistronic chimeric antigen receptors and their uses

    The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted May 14, 2024 Β· Expires May 9, 2044

    granted
  3. US 11981740

    BAFF-R antibodies and uses thereof

    The Board of Regents of the University of Texas System Β· Granted May 14, 2024 Β· Expires May 9, 2044

    granted
  4. US 11980607

    Methods of treating malignant lymphoproliferative disorders

    ACTUATE THERAPEUTICS INC. Β· Granted May 14, 2024 Β· Expires May 9, 2044

    granted
  5. US 11981752

    Tumor associated monocyte/macrophage binding peptide and methods of use thereof

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE Β· Granted May 14, 2024 Β· Expires May 9, 2044

    granted
  6. US 11981760

    Therapeutic hydrogels and contact lens for corneal melting

    The Regents of the University of Colorado, a Body Corporate Β· Granted May 14, 2024 Β· Expires May 9, 2044

    granted
  7. US 11981724

    DNA antibody constructs for use against middle east respiratory syndrome coronavirus

    Inovio Pharmaceuticals, Inc. Β· Granted May 14, 2024 Β· Expires May 9, 2044

    granted
  8. US 11980637

    Compositions comprising nanosilica particles and their use in methods of activating T lymphocytes for therapy

    United Kingdom Research and Innovation Β· Granted May 14, 2024 Β· Expires May 9, 2044

    granted
  9. US 11981716

    Activatable interleukin-2 polypeptides and methods of use thereof

    Werewolf Therapeutics, Inc. Β· Granted May 14, 2024 Β· Expires May 9, 2044

    granted
  10. US 11981750

    Antigenic tripeptides derived from Mycobacterium avium subsp. paratuberculosis s-type strains, derivatives and uses thereof

    The United States of America, as represented by the Secretary of Agriculture Β· Granted May 14, 2024 Β· Expires May 9, 2044

    granted
  11. US 11981684

    Macrocyclic compounds and uses thereof

    TURNING POINT THERAPEUTICS, INC. Β· Granted May 14, 2024 Β· Expires May 9, 2044

    granted
  12. US 11982672

    Methods

    AUTOLUS LIMITED Β· Granted May 14, 2024 Β· Expires May 9, 2044

    granted
  13. US 11980633

    Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated Β· Granted May 14, 2024 Β· Expires May 9, 2044

    granted
  14. US 11981662

    Pyrazole derivatives with anticancer activity

    The Board of Regents of the University of Texas System Β· Granted May 14, 2024 Β· Expires May 9, 2044

    granted
  15. US 11981897

    Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression

    Ionis Pharmaceuticals, Inc. Β· Granted May 14, 2024 Β· Expires May 9, 2044

    granted
  16. US 11981700

    Pyrrolopyrimidine nucleosides and analogs thereof

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted May 14, 2024 Β· Expires May 9, 2044

    granted
  17. US 11981763

    Resin composition for stereolithographic modeling

    KURARAY NORITAKE DENTAL INC. Β· Granted May 14, 2024 Β· Expires May 9, 2044

    granted
  18. US 11981741

    Humanized anti-CD45 antibodies

    Actinium Phamaceuticals, Inc. Β· Granted May 14, 2024 Β· Expires May 9, 2044

    granted
  19. WO 2024094673

    RÉGIME DE TRAITEMENT À BASE DE PTH COMPRENANT DEUX COMPOSÉS PTH

    ASCENDIS PHARMA BONE DISEASES AS [DK] Β· Granted May 10, 2024 Β· Expires May 5, 2044

    granted
  20. WO 2024094329

    PRÉPARATION DE CAPSULE SOUS EMBALLAGE COQUE CONTENANT DU SULFATE D'ISAVUCONAZONIUM

    BASILEA PHARMACEUTICA INT AG ALLSCHWIL [CH] Β· Granted May 10, 2024 Β· Expires May 5, 2044

    granted
  21. US 11975081

    Bifunctional chelators and conjugates

    Actinium Phamaceuticals, Inc. Β· Granted May 7, 2024 Β· Expires May 2, 2044

    granted
  22. US 11976293

    Optimized lentiviral vector for stem cell gene therapy of hemoglobinopathies

    The Regents of the University of California Β· Granted May 7, 2024 Β· Expires May 2, 2044

    granted
  23. US 11975016

    2β€²-substituted-N6-substituted purine nucleotides for RNA virus treatment

    Atea Pharmaceuticals, Inc. Β· Granted May 7, 2024 Β· Expires May 2, 2044

    granted
  24. US 11975062

    Zika vaccines and immunogenic compositions, and methods of using the same

    Takeda Vaccines, Inc. Β· Granted May 7, 2024 Β· Expires May 2, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.